News and Press Releases
Press releases
Theralase® Patient Six Cancer-Free at Nine Months After Single Anti-Cancer Treatment
Press ReleaseToronto, Ontario – January 30, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated P...
Theralase® Completes $1.4 M Private Placement Equity Financing
Press ReleaseToronto, Ontario – January 9, 2019 Theralase Technologies Inc. (“Theralase®” or “Company”) (TSXV: TLT) (OTCQB: TLTFF) is pleased to announce that it has closed its previously announced non-brokered privateplacement offering (...
Health Canada Grants ITA Approval to Commence Phase II Clinical Study
Press ReleaseToronto, Ontario – December 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”)(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated P...
Theralase’s Rutherrin® Photo Dynamic Therapy Induces Immune Response to Destroy Human Brain Cancer Cells
Press ReleaseRutherrin® mediated Photo Dynamic Therapy improves cancer specific immune responses by switching the so called “Don’t eat me” signal that cancer cells use to trick the immune system into the “Eat me” signal on treated human gl...
Theralase® Granted Canadian Anti-Cancer Patent
Press ReleaseTheralase® Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells and When Laser Light Activated Destroy Them Toronto, Ontario – November 15, 2018 Theralase Technologies Inc. (“Theralase®” or the “Co...
Theralase® Release 3Q2018 Financial Statements
Press ReleaseToronto, Ontario – November 29, 2018 “Theralase®” or the “Company” (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PD...
Patient Five Cancer-Free After Single PDT Treatment
Press ReleaseTheralase® Provides Update on 9 months Post Treatment Cystoscopy Analysis Toronto, Ontario – November 8, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceut...
Theralase® Announces Completion of Non-Brokered Private Placement for Approximately $1.1 million
Press ReleaseToronto, Ontario – October 3, 2018 Theralase Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (th...
Theralase® Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System
Press ReleaseTheralase® Affiliated Researchers Present New Data that Demonstrates the Application of Theralase’s Lead Photo Dynamic Compound, TLD-1433, in the Destruction of Gastrointestinal Dysplasia and Esophageal Cancer. Toronto, Ontario – O...
Health Canada Approves Commencement of Phase II Clinical Study
Press ReleaseToronto, Ontario – September 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
